Crinetics Pharmaceuticals CRNX Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Crinetics Pharmaceuticals (CRNX) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five of $459.6M in Q1 2026.